Clinical Evaluation of Anlotinib Combined with Programmed Death-1 Inhibitors in the Treatment of Advanced Gastric Cancer
Objective To investigate the clinical efficacy of anlotinib combined with programmed death-1(PD-1)inhibitors in the treatment of advanced gastric cancer.Methods A total of 82 patients with advanced gastric cancer admitted to the hospital from July 2021 to July 2023 were selected and divided into the observation group and the control group by the random number table method,with 41 cases in each group.The patients in the two groups were treated with PD-1 inhibitors,on this basis,the patients in the observation group received Anlotinib Hydrochloride Capsules.Both groups were treated for three courses with three weeks as one course.Results The objective response rate(ORR)and disease control rate(DCR)in the observation group were 34.15%and 73.17%respectively,which were significantly higher than 12.20%and 46.34%in the control group(P<0.05).After treatment,the carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 242(CA242),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)levels in the observation group were significantly lower than those in the control group(P<0.05);the vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF),matrix metalloproteinase-9(MMP-9)levels were significantly lower than those in the control group(P<0.05);the CD4+level and CD4+/CD8+were significantly higher than those in the control group,and the CD8+level was significantly lower than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Anlotinib combined with PD-1 inhibitors can significantly improve the tumor markers,VEGF and T lymphocytes levels in patients with advanced gastric cancer.
万方数据
维普
